Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2019

View Archived Issues

RC-01 demonstrates promising efficacy in murine pneumonia and urinary tract infection models

Strictinin reduces TNBC proliferation, survival and motility via inhibition of ROR1

HMCES, in detail

Goldfish genome brings zebrafish insight

Results from phase II study of trabectedin in recurrent grade II or III meningioma

Hanmi presents phase I results for belvarafenib in patients with solid tumors

First-in-human data presented for SRA-737

Cerecor announces promising final results from phase I study of CERC-301

First patient enrolled in phase II study of rimegepant for refractory trigeminal neuralgia

Enrollment begins in phase III study of camrelizumab plus rivoceranib for HCC

Results from phase II study presented for sintilimab in patients with R/R ENKTL

SciFluor Life Sciences divulges KCNQ2/3 activators

Boehringer Ingelheim patents GluN2B negative allosteric modulators

Parkinson's disease starts in gut, moves to brain: study

GlaxoSmithKline synthesizes new IDO1 inhibitors

Esteve Pharmaceuticals patent describes analgesic agents

Shanghai Meiyue Biotech presents new thrombin inhibitors

European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

Boston Biomedical to discontinue CanStem111P study of napabucasin in pancreatic cancer

Boehringer Ingelheim and Yuhan collaborate on GLP1R/FGF21R agonist for NASH

CD45 could be a novel target for B-cell malignancies

Holy Stone studies CA-102N in first-in-human trial for advanced solid tumors

Early diagnosis of X-linked myotubular myopathy in an infant

PTC Therapeutics and Odylia collaborate on gene therapies for rare inherited retinal diseases

CNOT2 deletion identified as responsible for the phenotypes of the 12q15 microdeletion syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...